Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of 50 mg, 100 mg and 200 mg PP4001 Twice Daily for the Treatment of Burning During Urination, Pain, and Urination Frequency Associated With Uncomplicated Urinary Tract Infection
Conditions
Interventions
PP4001
PP4001
+2 more
Locations
25
United States
Drug Research and Analysis Corp.
Montgomery, Alabama, United States
Mesa Family Medical Center/Clincal Research Advantage
Mesa, Arizona, United States
Desert Clinical Research/Clinical Research Advantage
Mesa, Arizona, United States
Central Phoenix Medical Clinic/Clinical Research Advantage
Phoenix, Arizona, United States
Northern California Research
Sacramento, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Start Date
July 1, 2011
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2011
Last Updated
October 19, 2011
NCT05488340
NCT07246837
NCT07308808
NCT04876131
NCT07233473
NCT07239219
Lead Sponsor
Pinnacle Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions